LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
A holder of LFST common stock has filed to potentially sell up to 500,000 shares through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $5,756,737.55. The issuer had 382,055,609 common shares outstanding. The shares to be sold include stock received as restricted stock vesting on March 6, 2025 for 82,616 shares and on March 7, 2025 for 417,384 shares, both described as compensation.
LifeStance Health Group, Inc. is the subject of an amended Schedule 13G filing by a group of Summit Partners-affiliated investment funds reporting passive beneficial ownership of its common stock. The reporting group, led by Summit Partners, L.P., reports beneficial ownership of 23,310,115 shares of common stock, representing 6.10% of the class, based on 382,055,609 shares outstanding as of July 29, 2026.
The individual Summit funds report shared voting and dispositive power over their respective positions, including 14,274,150 shares (3.74%) held by Summit Partners Growth Equity Fund IX-A, L.P. and 8,912,582 shares (2.33%) held by Summit Partners Growth Equity Fund IX-B, L.P. Smaller positions are reported by related Summit entities. Investment and voting decisions for the reported securities are delegated to Summit Partners, L.P. through a three-person investment committee. The reporting entities and committee members expressly disclaim beneficial ownership beyond what is reported for purposes of Section 13(d) and 13(g).
LFST received a Rule 144 notice indicating that Citadel Securities, LLC plans to sell up to 13,643,207 shares of Common Stock, par value $0.01 per share, on the NASDAQGS on or after August 10, 2026. The filing lists an aggregate market value of $147,892,363.88 for these shares, with 382,055,609 shares of Common Stock outstanding. The seller originally acquired 184,902,826 shares from the issuer on June 9, 2021 in a reorganization that preceded the company’s initial public offering, described as a contribution of limited partner interests for shares of Common Stock.
LifeStance Health Group Inc. received a notice of proposed resale of its common stock under Rule 144. A holder working with Citadel Securities LLC intends to sell up to 1,742,770 shares of LifeStance common stock on NASDAQ, with an indicated aggregate market value of $18,508,217.40.
The filing states that LifeStance had 382,055,609 shares outstanding and that the seller’s equity interests were originally acquired in pre-IPO transactions on June 10, 2021.
LifeStance Health Group Inc. has filed a notice for a proposed resale of its common stock. The filing indicates a planned sale of 1,088,162 shares, with an aggregate market value of $11,556,280.44, to be sold on or after 08/10/2026 on NASDAQ through Citadel Securities LLC. The seller previously purchased 18,446,106 equity interests in LifeStance in a pre-IPO transaction on 06/10/2021.
Citadel Securities LLC filed a notice of proposed sale of 1,626 shares of LifeStance Health Group Inc. common stock on the NASDAQ, with an aggregate market value of $17,268.12 and an expected sale date of August 10, 2026. These shares relate to equity interests acquired in pre-IPO transactions on June 10, 2021, when 27,568 equity interests in LifeStance Health Group Inc. were purchased before the company’s initial public offering.
LifeStance Health Group Inc. has a stockholder planning to sell 12,165 shares of common stock on NASDAQ through Citadel Securities LLC, located in Miami, Florida. The proposed sale has an aggregate market value of $129,192.30, with 382,055,609 common shares of the issuer outstanding. The seller previously acquired 206,219 equity interests in LifeStance Health Group Inc. in a pre-IPO transaction dated June 10, 2021. The planned sale date is stated as August 10, 2026.
LifeStance Health Group Inc. is the subject of a notice by Citadel Securities LLC relating to potential resales of its common stock under Rule 144. Citadel reports that it acquired equity interests in LifeStance on 06/10/2021 through Pre-IPO Transactions.
The filing lists a planned sale of 21,572 shares of common stock tied to those pre-IPO acquisitions, with a stated sale date of 06/10/2021. It also reports that, during the past three months, 1,273 shares of LifeStance common stock were sold on NASDAQ for an aggregate market value of $13,519.26. Shares outstanding are reported as 382,055,609 as of 08/10/2026; this is a baseline figure, not the amount being sold.
A holder of LFST common stock filed a Form 144 indicating an intent to sell up to 47,912 common shares through Fidelity Brokerage Services on NASDAQ on 08/10/2026, with an aggregate value of 519,845.20. The filing also reports recent restricted stock vesting as compensation of 19,815 shares on 03/06/2026, 14,707 shares on 03/08/2026, and 13,390 shares on 03/09/2026.